Melbourne researchers have shown they can stop leukaemia in its tracks by targeting a protein that puts the handbrake on cancer cell growth.
The researchers discovered that targeting a protein called Hhex could cure acute myeloid leukaemia (AML) in preclinical disease models, and could be a key target for new therapies for human leukaemia.
Dr Ben Shields and Dr Matt McCormack from the Walter and Eliza Hall Institute’s Cancer and Haematology division discovered that loss of the Hhex protein put the handbrake on leukaemia cell growth and division. The protein is a critical factor enabling AML cells to grow uncontrollably, a hallmark of cancer.
AML is an aggressive blood cancer that appears suddenly, grows quickly and has a poor prognosis. Existing treatments for AML are associated with serious side-effects. About three quarters of patients relapse after only a short period of treatment, with a five-year survival rate of just 24 per cent.
Dr McCormack said discovering how AML overcame normal cellular controls on growth and division was a breakthrough in the search for new therapies.
“There is an urgent need for new therapies to treat AML,” said Dr McCormack. “We showed blocking the Hhex protein could put the brakes on leukaemia growth and completely eliminate AML in preclinical models. This could be targeted by new drugs to treat AML in humans.”
He said Hhex was a particularly attractive therapeutic target because it was overproduced in leukaemia and, while essential for leukaemia cell growth, was not needed by healthy blood cells.
“Most existing treatments for AML are not cancer cell-specific, and unfortunately kill off healthy cells in the process,” Dr McCormack said.
“Hhex is only essential for the leukaemic cells, meaning we could target and treat leukaemia without toxic effects on normal cells, avoiding many of the serious side-effects that come with standard cancer treatments. We also know that most people with AML have increased levels of Hhex, often associated with adverse outcomes, further indicating it is an important target for new AML drugs.”
Dr Shields said AML cells switched off the controls that strictly manage cell growth and division. “Every cell has control genes that are activated when a cell is stressed, such as in the early stages of cancer, and stop the damaged cell from reproducing.” Dr Shields said.
While these control genes are still present in AML cells, they are switched off through a process called epigenetic modification. “Hhex works by recruiting epigenetic factors to growth control genes, effectively silencing them. This allows the leukaemia cells to reproduce and accumulate more damage, contributing to the speed of AML progression,” Dr Shields said.
Dr McCormack said drugs that inhibit epigenetic modification had been previously used to treat AML, but caused significant toxicity because their targets were also required for normal blood cell function.
“Unlike the epigenetic factors targeted previously, Hhex only regulates a small number of genes and is dispensable for normal blood cells. This gives us a rare opportunity to kill AML cells without causing many side effects,” said Dr McCormack. “We now hope to identify the critical regions of the Hhex protein that enable it to function, which will allow us to design much-needed new drugs to treat AML.”
The Latest on: Leukaemia
via Google News
The Latest on: Leukaemia
- I thought I had long Covid – it was leukaemiaon May 15, 2022 at 4:30 am
I couldn't catch my breath after walking upstairs, and heard what sounded like a heartbeat in my head when I was trying to sleep.
- Ex-England ace who always gets trolled thought leukaemia diagnosis was a "life sentence"on May 13, 2022 at 9:27 am
EXCLUSIVE: Ex-England star Geoff Thomas MBE is doing all he can to help those battling cancer after his own fight with leukaemia - and Didier Deschamps is at the heart of his latest contribution ...
- Mum who lost 18-month-old daughter to leukaemia sets up grief and trauma eventon May 12, 2022 at 2:00 pm
A mum who lost her daughter to leukaemia has set up an online learning retreat in her memory. Leah Morgan, a yoga teacher and grief coach for Still We Rise coaching, organised the event in memory of ...
- Race Oncology secures governance approval for human trials of leukaemia drug candidateon May 12, 2022 at 7:44 am
The open-label Phase 1 trial will recruit up to 60 patients with confirmed extramedullary acute myeloid leukaemia (AML) at up to 10 ...
- Scientists develop new method to improve CAR T therapy for Acute Myeloid Leukaemia patientson May 11, 2022 at 2:03 am
The team of scientists initiated their study with a CAR T construct directed against an antigen called CD70 that is present in larger numbers on AML cells than on normal myeloid cells.
- Drug to tackle leukaemia gets go-aheadon May 9, 2022 at 4:00 pm
The Scottish Medicines Consortium approved venetoclax after studies found it could offer adult patients with chronic lymphocytic leukaemia a better chance at survival when used with another drug. Dr ...
- SA scientists in major leukaemia advanceon May 8, 2022 at 3:30 am
South Australian scientists have made a significant advance in overcoming drug resistance among patients with acute myeloid leukaemia, a rare blood cancer that kills most sufferers within a few years.
- Norfolk leukaemia patient in diverse heritage donor callon May 6, 2022 at 11:38 pm
Jackie Higham has rare acute lymphoblastic leukaemia; a blood disorder which tends to affect children rather than adults, according to Anthony Nolan A woman of Lebanese descent in desperate need of a ...
- Teen who battled three forms of leukaemia in intensive care soars up Irish Junior Open ranks despite being new to golfon May 5, 2022 at 10:00 am
A TEENAGER who spent five days in intensive care battling three forms of leukaemia is on the leaderboard of the Irish Junior Open Tour, despite only taking up the game before Covid-19 lockdown. Oran ...
via Bing News